Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SBFM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSunshine Biopharma announces FY 2025 financial results via press release
Filed April 9, 2026 · Period ending April 6, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release on April 6, 2026 disclosing full-year 2025 financial results. Actual figures and performance metrics are in the attached press release (Exhibit 99.1), not in the 8-K body itself.
Item 2.02 verify on EDGAR →
Summary
Sunshine Biopharma filed an 8-K to announce it released its 2025 annual financial results on April 6, 2026. This is a standard earnings disclosure filing. The 8-K itself contains no financial details—those are in the attached press release (Exhibit 99.1).
For retail investors, this means the company has reported its full-year performance, but you'll need to review the actual press release to understand revenue, expenses, cash position, and any forward guidance.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Sunshine Biopharma filed an 8-K attaching a press release; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Exhibit No. | Description | 99.1 | Press Release
The 8-K attaches a press release as Exhibit 99.1. The filing body provides no details about the press release content, so the nature and materiality of the disclosure cannot be determined from this 8-K text alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify